Sanofi’s new QIV may earn up to $384m in 2022

sanofi quadrivalent influenza (Sean McMenemy

Sanofi Pasteur's newly-approved quadrivalent influenza vaccine (QIV) [Sanofi nabs quadrivalent flu vaccine FDA approval for under 2s] may earn as much as $384 million in 2022, according to a forecast by GlobalData.

"With the addition of a fourth strain, participating vaccine manufacturers have undertaken a step towards developing a universal vaccine that could potentially protect against both seasonal and pandemic influenza strains," said Ramya Kartikeyan, PhD PPM, GlobalData's Head of Infectious Disease. Kartikeyan expects that a new wave of QIVs will cannibalize sales revenues generated by trivalent vaccines before fully supplanting them as the standard for vaccination.

Read the GlobalData commentary here >

What do you think? You can leave a comment in the box below, or on LinkedIn group discussion. Want more from Vaccine Nation? Sign up to our newsletter for free hereIf you want to know more about strategy and innovation in vaccines, you might be interested in attending the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille.

Leave a Reply

Your email address will not be published. Required fields are marked *